About US
Contact us
-
Apellis' weak quarter for Syfovre signals uphill climb for geographic atrophy med: analystDespite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic atrophy market is a tough nut to crack. Syfovre—which became the first2025/5/8
-
As Bayer's restructuring rolls on, Kerendia and Nubeqa power pharma unit to surprising sales increaseThanks to hefty salesincreasesfrom kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of blockbust2025/5/8
-
Roche spotlights Perjeta's staying power with 10-year breast cancer survival resultsRoche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer. Now, the company can further back up the regimen’s prowess with a2025/5/6
-
Bluebird bio warns of potential bankruptcy as buyout faces another delayBluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers Carlyle and SK Capital to extend their offer deadline once again. Bluebir2025/5/6
-
Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and PfizerAfter issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody linvoseltamab, the company has crossed the regulatory finish line with its new dru2025/4/29
-
As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defenseWith an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. That’s how Biljana Naumovic, president of J&J’s U.S. solid tumor business, de2025/4/29
-
Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trialAkeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit Therap2025/4/24
-
Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtypeAkeso is on a winning streak. Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso haswon the FDA’s go-aheadfor its PD-1 inhibitor penpulimab co-developed with2025/4/24
-
US court decision stops compounders from making knockoffs of Novo Nordisk's semaglutideMakers of knockoff in-demand weight loss drugs are fast running out of options to manufacture them legitimately as a federal court this week dismissed an attempt by compounding pharmacies to continue2025/4/22
-
Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyoutMerck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. The German drugmakerconfirmed(PDF) it is in late-stage talks about buying the rare cancer biopharma for around2025/4/22